Why the study?
Approximately 50% of patients with severe mitral regurgitation referred for surgery have prohibitive surgical risk, making MitraClip an alternative, but mid-term outcomes required evaluation.
Population
162 consecutive patients with ≥2+ MR and high risk for conventional surgical therapy
Comparison
MitraClip implantation
Design
Single-centre observational study
Follow-up
Mean 819.8 ± 671.1 days
Authors
Loading...
Symptomatic gains with MitraClip in high-risk MR warrant monitoring; leaves open randomized survival data.
Percutaneous mitral valve edge-to-edge repair provides significant symptomatic improvement and high procedural success in high-surgical-risk patients, though long-term mortality remains high, particularly in those with LVEF <30% or secondary MR.
Demir et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: